[{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"7300e9bc-2738-46d0-acf9-18bff85ed65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02212262","created_at":"2021-01-18T10:21:42.879Z","updated_at":"2024-07-02T16:35:37.643Z","phase":"","brief_title":"Role of Osteocytes in Myeloma Bone Disease","source_id_and_acronym":"NCT02212262","lead_sponsor":"Attaya Suvannasankha","biomarkers":" DKK1 • FGF23","pipe":"","alterations":" ","tags":["DKK1 • FGF23"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 10/07/2014","start_date":" 10/07/2014","primary_txt":" Primary completion: 02/05/2022","primary_completion_date":" 02/05/2022","study_txt":" Completion: 02/05/2022","study_completion_date":" 02/05/2022","last_update_posted":"2023-09-08"},{"id":"c0fb26e4-588f-4ea3-80da-f8b88b7324e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02702388","created_at":"2021-07-05T16:52:02.815Z","updated_at":"2025-02-25T16:04:25.407Z","phase":"Phase 2","brief_title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","source_id_and_acronym":"NCT02702388","lead_sponsor":"Eisai Inc.","biomarkers":" FGF23 • TG","pipe":"","alterations":" ","tags":["FGF23 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 241","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2021-11-24"},{"id":"7c346db6-4174-4292-8a2b-5cb3e58e0611","acronym":"","url":"https://clinicaltrials.gov/study/NCT05105464","created_at":"2021-11-03T12:53:05.612Z","updated_at":"2024-07-02T16:36:21.590Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05105464","lead_sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","biomarkers":" PD-L1 • FGFR • KDR • CEACAM5 • FGF23","pipe":"","alterations":" ","tags":["PD-L1 • FGFR • KDR • CEACAM5 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SYHA1815"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-11-03"},{"id":"75de18f5-155e-45d7-85e4-d37abf65ca4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01976741","created_at":"2021-03-02T12:23:56.095Z","updated_at":"2025-02-25T17:07:13.668Z","phase":"Phase 1","brief_title":"Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)","source_id_and_acronym":"NCT01976741","lead_sponsor":"Bayer","biomarkers":" FGF23","pipe":" | ","alterations":" FGFR mutation","tags":["FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 12/30/2013","start_date":" 12/30/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 01/09/2020","study_completion_date":" 01/09/2020","last_update_posted":"2021-05-06"},{"id":"077d9162-d559-485c-9149-55c8476adb7a","acronym":"THERANOVA","url":"https://clinicaltrials.gov/study/NCT03211676","created_at":"2021-01-18T15:50:25.999Z","updated_at":"2024-07-02T16:36:46.078Z","phase":"","brief_title":"Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer","source_id_and_acronym":"NCT03211676 - THERANOVA","lead_sponsor":"Poitiers University Hospital","biomarkers":" IL6 • TNFA • B2M • FGF23 • IL1B • LEP • MB","pipe":"","alterations":" ","tags":["IL6 • TNFA • B2M • FGF23 • IL1B • LEP • MB"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 03/14/2018","primary_completion_date":" 03/14/2018","study_txt":" Completion: 06/14/2018","study_completion_date":" 06/14/2018","last_update_posted":"2020-04-13"},{"id":"bad33fae-f9c7-474e-879f-6eabe449864a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02038673","created_at":"2021-01-18T09:21:26.925Z","updated_at":"2024-07-02T16:37:05.880Z","phase":"Phase 1","brief_title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","source_id_and_acronym":"NCT02038673","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FGF19 • FGF23","pipe":"","alterations":" ","tags":["FGF19 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP5878"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 07/19/2017","primary_completion_date":" 07/19/2017","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-10-22"},{"id":"d59f7b11-7111-4ed8-aa03-7fac168afde2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02592785","created_at":"2021-01-17T17:39:10.660Z","updated_at":"2025-02-25T17:08:27.420Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02592785","lead_sponsor":"Bayer","biomarkers":" FGFR1 • FGF23","pipe":" | ","alterations":" FGFR3 mutation","tags":["FGFR1 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 02/05/2017","primary_completion_date":" 02/05/2017","study_txt":" Completion: 12/06/2017","study_completion_date":" 12/06/2017","last_update_posted":"2018-04-18"}]